SKNY-1 is an oral cannabinoid analog designed to promote weight loss while preserving lean body mass, addressing a key limitation of current therapies.
SKNY-1 is designed to engage complementary pathways involved in metabolic regulation and reward-associated behavior.
SKNY-1 exhibits differing affinity and activity profiles across CB1, CB2, and MAO-B.
In a zebrafish model of obesity, SKNY-1 produced significant weight reduction without a corresponding change in whole-body density.
Whole-Body Density Maintained
~30% Weight Reduction
SKNY-1 Normalizes Hepatic Triglyceride Levels
SKNY-1 Normalizes Leptin-to-Ghrelin Expression Ratio
These findings are preclinical. Additional mammalian, PK, and toxicology work continues as SKNY-1 advances toward an IND, targeted 1H 2027.*
*Subject to FDA clearance and other regulatory and operational factors.
Learn more about MIRA Pharmaceuticals
See how MIRA is advancing three oral programs across pain and obesity.
